Cited by 653Cancer-related Molecular PathwaysUbiquitin and proteasome pathwaysHeat shock proteins research

The DOI matches its Crossref record; 134 of the 144 references it cites were found in a registry or an index.

MDM2 — master regulator of the p53 tumor suppressor protein

Momand, Jamil, Wu, Hsiao-Huei, Dasgupta, Gargi·2000·Gene

Open this paper in CoChat — free account

Abstract

MDM2 is an oncogene that mainly functions to modulate p53 tumor suppressor activity. In normal cells the MDM2 protein binds to the p53 protein and maintains p53 at low levels by increasing its susceptibility to proteolysis by the 26S proteosome. Immediately after the application of cellular stress, the ability of MDM2 to bind to p53 is blocked or altered in a fashion that prevents MDM2-mediated degradation. As a result, p53 levels rise, causing cell cycle arrest or apoptosis. In this review, we present evidence for the existence of three highly conserved regions (CRs) shared by MDM2 proteins and MDMX proteins of different species. These highly conserved regions encompass residues 42-94 (CR1), 301-329 (CR2), and 444-483 (CR3) on human MDM2. These three domains are respectively important for binding p53, for binding the retinoblastoma protein, and for transferring ubiquitin to p53. This review discusses the major milestones uncovered in MDM2 research during the past 12 years and potential uses of this knowledge in the fight against cancer.

Integrity signals

Registry

Crossref · 10.1016/s0378-1119(99)00487-4

Cites

134 of 134 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

THE UBIQUITIN SYSTEM
Hershko, A., & Ciechanover, A. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.425 · Cited by 8,840
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
Toshiyuki, M., & Reed, J. C. (1995) · Cell · doi:10.1016/0092-8674(95)90412-3 · Cited by 4,063
Participation of p53 protein in the cellular response to DNA damage.
Kastan, M. B., Onyekwere, O. C., Sidransky, D., Vogelstein, B., & Craig, R. W. (1991) · PubMed · Cited by 3,761
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312
The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
Self-citation

Show all 144 references

Sorted by citations

Items 401–500 of 653

Impact of MDM2 polymorphism
Chaar, I., Arfaoui, A. T., Amine, E. H. O. E., Mahmoud, L. K. B., Khiari, M., Sammoud, S., Lounis, M. A., Amara, S., Gharbi, L., Hmida, A. B., et al. (2012) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e32834bdf84 · Cited by 14
SATB2 and MDM2 Immunoexpression and Diagnostic Role in Primary Osteosarcomas of the Jaw
Owosho, A. A., Ladeji, A. M., Adesina, O. M., Adebiyi, K. E., Olajide, M. A., Okunade, T., Palmer, J., Kehinde, T., Vos, J. A., Cole, G., et al. (2021) · Dentistry Journal · doi:10.3390/dj10010004 · Cited by 14
MDM2-BCL-XL PROTACs enable degradation of BCL-XL and stabilization of p53
Chang, M., Gao, F., Chen, J., Gnawali, G. R., & Wang, W. (2022) · Acta Materia Medica · doi:10.15212/amm-2022-0022 · Cited by 18
A Synthetic Form of Frizzled 8-Associated Antiproliferative Factor Enhances p53 Stability through USP2a and MDM2
Kim, J., Keay, S. K., You, S., Loda, M. F., & Freeman, M. R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050392 · Cited by 14
p53 Pathway Alterations in Brain Tumors
Yin, S., & Meir, E. G. V. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-553-8_14 · Cited by 15
Janus face-like effects of Aurora B inhibition: antitumoral mode of action versus induction of aneuploid progeny
Wiedemuth, R., Klink, B., Fujiwara, M., Schröck, E., Tatsuka, M., Schackert, G., & Temme, A. (2016) · Carcinogenesis · doi:10.1093/carcin/bgw083 · Cited by 15
Broadly expressed tumour?associated proteins as targets for cytotoxic T lymphocyte-based cancer immunotherapy
Bendle, G. M., Holler, A., Downs, A.-M., Xue, S., & Stauss, H. J. (2005) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.5.9.1183 · Cited by 14
Differentially expressed genes from the glioblastoma cell line SHG-44 treated with all-trans retinoic acid in vitro
Zeng, Y., Yang, Z., Xu, J., Yang, M.-S., Zeng, Z.-X., & You, C. (2008) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2007.11.014 · Cited by 14
A spatiotemporal characterization of the effect of p53 phosphorylation on its interaction with MDM2
ElSawy, K. M., Sim, A. Y. L., Lane, D. P., Verma, C. S., & Caves, L. S. D. (2015) · Cell Cycle · doi:10.4161/15384101.2014.989043 · Cited by 14
Determinants of Retroviral-Mediated Gene Delivery to Mouse Spermatogonia1
Miguel, M. P. D., & Donovan, P. J. (2003) · Biology of Reproduction · doi:10.1095/biolreprod.102.005132 · Cited by 14
Ubiquitin Ligases in Malignant Lymphoma
Lim, M. S., & Elenitoba‐Johnson, K. S. J. (2004) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190410001663635 · Cited by 14
HER-2/Neu signaling and therapeutic approaches in breast cancer
Zhou, B. P., Li, Y., & Hung, M. (2002) · Breast Disease · doi:10.3233/bd-2002-15103 · Cited by 14
Multicomponent synthesis, structural and molecular dynamics simulation studies of a novel spirooxindole derivative
Mahesha, M., Sapnakumari, M., Chethan, B. S., Jinkle, T., Urs, M. V. D., Lingegowda, N. S., Lokanath, N. K., & S, N. S. (2024) · Chemical Physics Impact · doi:10.1016/j.chphi.2024.100467 · Cited by 13
Phospholipase D stabilizes HDM2 through an mTORC2/SGK1 pathway
Lyo, D., Xu, L., & Foster, D. A. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.04.148 · Cited by 13
Switching p 53 states by calcium: dynamics and interaction of stress systems
Alam, M. J., Devi, G. R., Ravins, Ishrat, R., Agarwal, S. M., & Singh, R. K. B. (2013) · Molecular BioSystems · doi:10.1039/c3mb25277a · Cited by 13
The mechanisms of regulation of Hdm2 protein level by serum growth factors
Phillips, A., Jones, C. J., & Blaydes, J. P. (2005) · FEBS Letters · doi:10.1016/j.febslet.2005.12.026 · Cited by 13
Regulation of collagen-derived antiangiogenic factors by p53
Assadian, S., & Teodoro, J. G. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.7.941 · Cited by 13
Pediatric Germ Cell Tumors
Frazier, A. L., & Amatruda, J. F. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-3431-5.00023-6 · Cited by 13
Direct Interaction of miRNA and circRNA with the Oncosuppressor p53: An Intriguing Perspective in Cancer Research
Bizzarri, A. R., & Cannistraro, S. (2021) · Cancers · doi:10.3390/cancers13236108 · Cited by 12
Preferential expression of Mdm2 oncogene during the development of neural crest and its derivatives in mouse early embryogenesis
Daujat, S., Neel, H., & Piette, J. (2001) · Mechanisms of Development · doi:10.1016/s0925-4773(01)00339-2 · Cited by 13
Data mining the p53 pathway in the Fugu genome: evidence for strong conservation of the apoptotic pathway
Bras, M. L., Bensaad, K., & Soussi, T. (2003) · Oncogene · doi:10.1038/sj.onc.1206424 · Cited by 13
SNP55, a new functional polymorphism of MDM2-P2 promoter, contributes to allele-specific expression of MDM2 in endometrial cancers
Okamoto, K., Tsunematsu, R., Tahira, T., Sonoda, K., Asanoma, K., Yagi, H., Yoneda, T., Hayashi, K., Wake, N., & Kato, K. (2015) · BMC Medical Genetics · doi:10.1186/s12881-015-0216-8 · Cited by 12
Molecular Interaction Fields and 3D-QSAR Studies of p53−MDM2 Inhibitors Suggest Additional Features of Ligand−Target Interaction
Dezi, C., Carotti, A., Magnani, M., Baroni, M., Padova, A., Cruciani, G., Macchiarulo, A., & Pellicciari, R. (2010) · Journal of Chemical Information and Modeling · doi:10.1021/ci100113p · Cited by 12
Novel MDM2 splice variants identified from oral squamous cell carcinoma
Sam, K. K., Gan, C. P., Yee, P. S., Chong, C., Lim, K. P., Karen‐Ng, L. P., Chang, W. S., Nathan, S., Rahman, Z. A. A., Ismail, S. M., et al. (2012) · Oral Oncology · doi:10.1016/j.oraloncology.2012.05.016 · Cited by 12
S100A1 blocks the interaction between p53 and mdm2 and decreases cell proliferation activity
Dowarha, D., Chou, R., & Yu, C. (2020) · PLoS ONE · doi:10.1371/journal.pone.0234152 · Cited by 12
Identification of spliced variants of the proto‐oncogene hdm2 in colorectal cancer
Yu, Z., Zhang, B., Cui, B., Wang, Y., Han, P., & Wang, X. (2011) · Cancer · doi:10.1002/cncr.26330 · Cited by 12
Study of MDM2 and SUMO-1 expression in actinic cheilitis and lip cancer
Alves, M. G. O., Delgado, A. D. M., Balducci, I., Carvalho, Y. R., Cavalcante, A. S. R., & Almeida, J. D. (2014) · Archives of Dermatological Research · doi:10.1007/s00403-014-1500-8 · Cited by 12
RETRACTED ARTICLE: Hypermethylation of the 5′ CpG island of the p14ARF flanking exon 1β in human colorectal cancer displaying a restricted pattern of p53 overexpression concomitant with increased MDM2 expression
Nyiraneza, C., Sempoux, C. L., Detry, R. J., Kartheuser, A. H., & Dahan, K. (2012) · Clinical Epigenetics · doi:10.1186/1868-7083-4-9 · Cited by 12
Retracted
Prognostic value of p53 and MDM2 Expression in Bilharziasis-Associated Squamous Cell Carcinoma of the Urinary Bladder
El-Kenawy, A. E.-M., El-kott, A. F., & Khalil, A. (2003) · The International Journal of Biological Markers · doi:10.5301/jbm.2008.2927 · Cited by 12
GC-selective DNA-binding antibiotic, Mithramycin A, reveals multiple points of control in the regulation of Hdm2 protein synthesis
Phillips, A., Darley, M., & Blaydes, J. P. (2006) · Oncogene · doi:10.1038/sj.onc.1209451 · Cited by 12
Search for germline alterations in CDKN2A/ARF and CDK4 of 42 Jewish melanoma families with or without neural system tumours
Marian, C., Scope, A., Laud, K., Friedman, E., Pavlotsky, F., Yakobson, E., Paillerets, B. B., & Azizi, E. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602629 · Cited by 12
Enhanced degradation of MDM2 by a nuclear envelope component, mouse germ cell-less
Masuhara, M., Nagao, K., Nishikawa, M., Kimura, T., & Nakano, T. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)01497-9 · Cited by 12
Effects of creatine monohydrate supplementation on exercise-induced apoptosis in athletes: A randomized, double-blind, and placebo-controlled study
Rahimi, R., Mirzaei, B., Rahmani-Nia, F., & Salehi, Z. (2015) · Journal of Research in Medical Sciences · doi:10.4103/1735-1995.168320 · Cited by 11
Cloning and characterization of the human gene DERP6, which activates transcriptional activities of p53
Yuan, J., Tang, W., Luo, K., Chen, X., Gu, X., Wan, B., & Yu, L. (2006) · Molecular Biology Reports · doi:10.1007/s11033-006-6273-5 · Cited by 11
Exploiting microRNA and mRNA profiles generatedin vitrofrom carcinogen-exposed primary mouse hepatocytes for predictingin vivogenotoxicity and carcinogenicity
Rieswijk, L., Brauers, K. J. J., Coonen, M. L. J., Jennen, D. G. J., Breda, S. G. J. V., & Kleinjans, J. C. S. (2016) · Mutagenesis · doi:10.1093/mutage/gew027 · Cited by 11
p53 – ein natürlicher Krebskiller: Einsichten in die Struktur und Therapiekonzepte
Römer, L., Klein, C., Dehner, A., Kessler, H., & Büchner, J. (2006) · Angewandte Chemie · doi:10.1002/ange.200600611 · Cited by 12
Unleashing the power of DNA-encoded libraries for challenging targets in drug discovery
Du, N., Li, Y., Lou, Q., Zhang, G., Li, Y., & Li, Y. (2026) · Pharmaceutical Science Advances · doi:10.1016/j.pscia.2026.100115 · Cited by 10
Cisplatin binds to the MDM2 RING finger domain and inhibits the ubiquitination activity
Cao, K., Ding, X., Sheng, Y., Wang, Y., & Liu, Y. (2020) · Chemical Communications · doi:10.1039/d0cc00203h · Cited by 9
Caspase-3, p53 and Bcl-2 expression in basal cell carcinoma of the eyelid
Koyun, E., Karadağ, R., Özkanlı, Ş., Oğuztüzün, S., Koçdoğan, A. K., & Ozsoy, I. (2020) · Advances in Dermatology and Allergology · doi:10.5114/ada.2020.98285 · Cited by 10
A Study of T Cell Tolerance to the Tumor-Associated Antigen MDM2: Cytokines Can Restore Antigen Responsiveness, but Not High Avidity T Cell Function
Bendle, G. M., Xue, S., Holler, A., & Stauss, H. J. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000353 · Cited by 10
Expression and function of cell cycle proteins in rheumatoid arthritis synovial tissue.
Taranto, E., & Leech, M. T. (2006) · PubMed · doi:10.14670/hh-21.205 · Cited by 10
Rice protein reduces DNA damage by activating the p53 pathway and stimulating endogenous antioxidant response in growing and adult rats
Liang, M., Li, H., Wang, Z., Cai, L., & Yang, L. (2019) · Journal of the Science of Food and Agriculture · doi:10.1002/jsfa.9888 · Cited by 11
Navigating the complexity of p53-DNA binding: implications for cancer therapy
Thayer, K. M., Stetson, S., Caballero, F., Chiu, C., & Han, I. S. M. (2024) · Biophysical Reviews · doi:10.1007/s12551-024-01207-4 · Cited by 9
Transcription factor E4F1 as a regulator of cell life and disease progression
Sun, S., Zhong, B., Zeng, X. Y., Li, J., & Chen, Q. (2023) · Science Advances · doi:10.1126/sciadv.adh1991 · Cited by 9
Role of p53 Pathway Alterations in Uterine Carcinosarcomas (Malignant Mixed Müllerian Tumors)
Semczuk, A., Ignatov, A., Obrzut, B., Reventós, J., & Rechberger, T. (2014) · Oncology · doi:10.1159/000363574 · Cited by 9
Identification and expression of a novel MDM4 splice variant in human glioma
Wang, X., Sheng, P. X., Guo, X., Wang, J., Hou, L.-J., Hu, G., Luo, C., Dong, Y., & Lu, Y. (2013) · Brain Research · doi:10.1016/j.brainres.2013.07.054 · Cited by 9
Bifurcation in Cell Cycle Dynamics Regulated by p53
Alam, M. J., Kumar, S., Singh, V., & Singh, R. K. B. (2015) · PLoS ONE · doi:10.1371/journal.pone.0129620 · Cited by 9
Is it safe to utilize in vitro reconstituted human oral epithelium? An oncogenetic pathway study
Klingbeil, M. F. G., Mathor, M. B., Giudice, F. S., Yoshito, D., & Júnior, D. D. S. P. (2010) · Cell and Tissue Banking · doi:10.1007/s10561-010-9217-1 · Cited by 9
p53 Contributes to Differentiating Gene Expression following Exposure to Acetaminophen and Its Less Hepatotoxic Regioisomer Both In Vitro and In Vivo
Stamper, B. D., Garcia, M. L., Nguyen, D., Beyer, R. P., Bammler, T. K., Farin, F. M., Kavanagh, T. J., & Nelson, S. D. (2015) · Gene Regulation and Systems Biology · doi:10.4137/grsb.s25388 · Cited by 9
Molecular markers (c-erbB-2, p53) in breast cancer.
Agrawal, A. K., Jeleń, M., Rudnicki, J., Grzebieniak, Z., Żukrowski, P., & Nienartowicz, E. (2009) · Folia Histochemica et Cytobiologica · doi:10.2478/v10042-008-0059-7 · Cited by 9
Targeting the Cell Cycle to Kill Cancer Cells
Taylor, W. R., & Grabovich, A. (2009) · Elsevier eBooks · doi:10.1016/b978-0-12-369521-5.00017-8 · Cited by 9
Radiation Induced Cell Deaths
Eriksson, D., Riklund, K., Johansson, L. F., & Stigbrand, T. I. (2008) · Springer eBooks · doi:10.1007/978-1-4020-8696-0_12 · Cited by 9
Characterization of two peptide epitopes on Mdm2 oncoprotein that affect p53 degradation
Balass, M., Kalef, E., Maya, R., Wilder, S., Oren, M., & Katchalski‐Katzir, E. (2002) · Peptides · doi:10.1016/s0196-9781(02)00147-x · Cited by 9
Cytoplasmic Translocation of p53 by Human Cytomegalovirus Infection
Kwon, Y., Kim, J., Kim, J. H., & Hwang, E. S. (2013) · Journal of Bacteriology and Virology · doi:10.4167/jbv.2013.43.4.297 · Cited by 8
TP53 ‐Mutated Acute Myeloid Leukemia: Unanswered Questions
Bruzzese, A., Vigna, E., Martino, E. A., Labanca, C., Caridà, G., Mendicino, F., Lucia, E., Olivito, V., Puccio, N., Neri, A., et al. (2025) · Hematological Oncology · doi:10.1002/hon.70106 · Cited by 10
Suppression of the doxorubicin response by hypoxia-inducible factor-1α is strictly dependent on oxygen concentrations under hypoxic conditions
Osada‐Oka, M., Kuwamura, H., Imamiya, R., Kobayashi, K., Minamiyama, Y., Takahashi, K., Tanaka, M., & Shiota, M. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174845 · Cited by 7
Synthesis and biological evaluation of dual MDM2/XIAP inhibitors based on the tetrahydroquinoline scaffold
Albadari, N. G., Xie, Y., Liu, T., Wang, R., Gu, L., Zhou, M., Wu, Z., & Li, W. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115423 · Cited by 8
Ribosome biogenesis, altered metabolism and ribotoxic stress response in pancreatic ductal adenocarcinoma tumor microenvironment
Chaudhary, S., Siddiqui, J. A., Pothuraju, R., & Bhatia, R. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217484 · Cited by 8
p53 CRISPR Deletion Affects DNA Structure and Nuclear Architecture
Pozzo, A. R., Booth, S., Yu, P. L. I., Singh, M., Selivanova, G., & Mai, S. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9020598 · Cited by 8
Codimension-3 Bifurcation in the p53 Regulatory Network Model
Jiang, C., Zhang, Y., & Wang, W. (2021) · International Journal of Bifurcation and Chaos · doi:10.1142/s0218127421501042 · Cited by 8
A novel ataxia-telangiectasia mutated autoregulatory feedback mechanism in murine embryonic stem cells
Clyde, R. G., Craig, A. L., de Breed, L. A., Bown, J., Forrester, L., Vojtěšek, B., Smith, G. C. M., Hupp, T. R., & Crawford, J. W. (2009) · Journal of The Royal Society Interface · doi:10.1098/rsif.2008.0538 · Cited by 8
Activation et modifications post-traductionnelles de p53 après dommage de l’ADN
Leblanc, V., & May, P. (2002) · médecine/sciences · doi:10.1051/medsci/2002185577 · Cited by 13
NIAM-Deficient Mice Are Predisposed to the Development of Proliferative Lesions including B-Cell Lymphomas
Reed, S. M., Hagen, J., Muniz, V. P., Rosean, T. R., Borcherding, N. C., Sciegienka, S. J., Goeken, J. A., Naumann, P. W., Zhang, W., Tompkins, V. S., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0112126 · Cited by 8
Antisense approaches in drug discovery and development
Rayburn, E. R., Wang, W., Zhang, R., & Wang, H. (2006) · Birkhäuser-Verlag eBooks · doi:10.1007/3-7643-7414-4_10 · Cited by 8
mdm2-p53 Interaction: Lack of Correlation with the Response to 5-Fluorouracil in Advanced Colorectal Cancer
Paradiso, A., Ranieri, G., Simone, G., Silvestris, N., da Costa, A. C., Lena, M. D., Leone, A., Vallejo, C. T., & Lacava, J. A. (2002) · Oncology · doi:10.1159/000059576 · Cited by 8
Novel p53 reactivators that are synergistic with olaparib for the treatment of gynecologic cancers with mutant p53
Smith, L. E., Padilla, J. L., Licor, A., Steinkamp, M. P., Lagutina, I. V., Guo, Y. P., Devor, E. J., Pankratz, V. S., Sallmyr, A., Oyebamiji, O., et al. (2025) · Translational Oncology · doi:10.1016/j.tranon.2025.102522 · Cited by 7
p53 Genetics and Biology in Lung Carcinomas: Insights, Implications and Clinical Applications
Benitez, D. A., Cumplido-Laso, G., Olivera-Gómez, M., Pino, N. D. V.-D., Díaz-Pizarro, A., Mulero‐Navarro, S., Román-García, A., & Carvajal-González, J. M. (2024) · Biomedicines · doi:10.3390/biomedicines12071453 · Cited by 9
Targeting p53 as a Promising Therapeutic Option for Cancer By Re-Activating the Wt Or Mutant p53’s Tumor Suppression
Węsierska‐Gądek, J. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0175 · Cited by 7
Giant retroperitoneal liposarcoma treated with radical conservative surgery: A case report and review of literature
Lieto, E., Cardella, F., Erario, S., Sorbo, G. D., Reginelli, A., Galizia, G., Urraro, F., Panarese, I., & AURICCHIO, A. (2022) · World Journal of Clinical Cases · doi:10.12998/wjcc.v10.i19.6636 · Cited by 7
Monitoring the Activation of the DNA Damage Response Pathway in a 3D Spheroid Model
Mondésert, O., Frongia, C., Clayton, O., Boizeau, M.-L., Lobjois, V., & Ducommun, B. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134411 · Cited by 7
ATM: From Phenotype to Functional Genomics — And Back
Shiloh, Y. (2002) · Springer eBooks · doi:10.1007/978-3-662-04667-8_4 · Cited by 7
Regulation of expression of the p21CIP1 gene by the transcription factor ZNF217 and MDM2
Mantsou, A., Koutsogiannouli, E. A., Haitoglou, C., Papavassiliou, A. G., & Papanikolaou, N. A. (2016) · Biochemistry and Cell Biology · doi:10.1139/bcb-2016-0026 · Cited by 7
Mathematical analysis of a generalised p53-Mdm2 protein gene expression model
Piotrowska, M. J., Bartłomiejczyk, A., & Bodnar, M. (2018) · Applied Mathematics and Computation · doi:10.1016/j.amc.2018.01.014 · Cited by 7
Regulated Nuclear Transport
Schüller, C., & Ruis, H. (2002) · Results and problems in cell differentiation · doi:10.1007/978-3-540-44603-3_9 · Cited by 7
Targeting MDM2 for the development of a new cancer therapy: progress and challenges
Aguilar, A., Thomas, J. E., & Wang, S. (2023) · Medicinal Chemistry Research · doi:10.1007/s00044-023-03102-1 · Cited by 6
Citrullination at the N‐terminal region of MDM2 by the PADI4 enzyme
Neira, J. L., Rizzuti, B., Palomino‐Schätzlein, M., Rejas, V., Abián, O., & Velázquez‐Campoy, A. (2025) · Protein Science · doi:10.1002/pro.70033 · Cited by 6
Sunlight Protection by Vitamin D Compounds
Mason, R. S., Dixon, K. M., Sequeira, V. B., & Gordon‐Thomson, C. (2011) · Elsevier eBooks · doi:10.1016/b978-0-12-381978-9.10100-3 · Cited by 6
Alterations of the Mdm2 C-Terminus Differentially Impact Its Function In Vivo
Pant, V., Aryal, N. K., Xiong, S., Chau, G. P., Fowlkes, N. W., & Lozano, G. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-2381 · Cited by 6
MDM2 for the practicing pathologist: a primer
Menon, A. A., Deshpande, V., & Suster, D. I. (2023) · Journal of Clinical Pathology · doi:10.1136/jcp-2022-208687 · Cited by 7
The Role of p53 in HIV Infection
Yaseen, M. M., Abuharfeil, N. M., & Darmani, H. (2023) · Current HIV/AIDS Reports · doi:10.1007/s11904-023-00684-8 · Cited by 7
Genetic Polymorphism of MDM2 SNP309 in Patients with Helicobacter Pylori-Associated Gastritis
Tongtawee, T., Dechsukhum, C., Leeanansaksiri, W., Kaewpitoon, S. J., Kaewpitoon, N., Loyd, R. A., Matrakool, L., & Panpimanmas, S. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.16.7049 · Cited by 6
Thyroid hormone upregulates MDM 2 in rat type I fibre: Implications for skeletal muscle mass regulation
Ramos, G. V., Cruz, A., Silva, W. J., Rozanski, A., Baptista, I. L., Silvestre, J. G., & Moriscot, A. S. (2017) · Acta Physiologica · doi:10.1111/apha.13003 · Cited by 6
Regulation of Actinomycin D induced upregulation of Mdm2 in H1299 cells
Li, L., Cui, D., Zheng, S. J., Lou, H., & Tang, J. (2011) · DNA repair · doi:10.1016/j.dnarep.2011.10.010 · Cited by 6
Current advances in the inhibition of the auto-regulatory interaction between the p53 tumour suppressor protein and MDM2 protein
Dart, D. A., Mansoor, M. S., Loadman, P. M., & Picksley, S. M. (2001) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.11.12.1825 · Cited by 6
Foldamer‐based Molecular Recognition
Becerril, J., Rodriguez, J. M., Saraogi, I., & Hamilton, A. D. (2007) · doi:10.1002/9783527611478.ch7 · Cited by 6
Wild Type p53 Conformation, Structural Consequences of p53 Mutations and Mechanisms of Mutant p53 Rescue
Joerger, A. C., Friedler, A., & Fersht, A. R. (2007) · Springer eBooks · doi:10.1007/978-1-4020-2922-6_17 · Cited by 6
Fibronectin Modulates the Expression of miRNAs in Prostate Cancer Cell Lines
Martinucci, B., Cucielo, M. S., Minatel, B. C., Cury, S. S., Caxali, G. H., Aal, M. C. E., Felisbino, S. L., Pinhal, D., Carvalho, R. F., & Delella, F. K. (2022) · Frontiers in Veterinary Science · doi:10.3389/fvets.2022.879997 · Cited by 5
FOLICation: Engineering approved drugs as potential p53–MDM2 interaction inhibitors for cancer therapy
Patil, S. P. (2013) · Medical Hypotheses · doi:10.1016/j.mehy.2013.10.014 · Cited by 5
Protein–Protein Interaction Inhibitors
Hardcastle, I. R. (2017) · Topics in medicinal chemistry · doi:10.1007/7355_2017_27 · Cited by 4
Expression levels of FBXW7 and MDM2 E3 ubiquitin ligases and their c‑Myc and p53 substrates in patients with dysplastic nevi or melanoma
Mozūraitienė, J., Gudlevičienė, Ž., Vincerževskienė, I., Laurinavičienė, A., & Pamedys, J. (2020) · Oncology Letters · doi:10.3892/ol.2020.12298 · Cited by 6
STEAP1 regulation and its influence modulating the response of LNCaP prostate cancer cells to bicalutamide, enzalutamide and apalutamide
Rocha, S. M., Nascimento, D., Cardoso, A., Passarinha, L. A., Socorro, S., & Maia, C. J. (2023) · Molecular Medicine Reports · doi:10.3892/mmr.2023.12939 · Cited by 5
Clinicopathological and Targeted Exome Gene Features of a Patient with Metastatic Acinic Cell Carcinoma of the Parotid Gland Harboring an ARID2 Nonsense Mutation and CDKN2A/B Deletion
Warner, W. A., Wong, D. J. L., Palma‐Diaz, F., Shibuya, T. Y., & Momand, J. A. (2015) · Case Reports in Oncological Medicine · doi:10.1155/2015/893694 · Cited by 6
Self-citation
N-terminal gelsolin fragment potentiates TRAIL mediated death in resistant hepatoma cells
Meyer, K., Kwon, Y., Ray, R. B., & Ray, R. (2017) · Scientific Reports · doi:10.1038/s41598-017-13131-7 · Cited by 5
Exploring cellular senescence as a tumor suppressor mechanism
Carnero, A., Blanco‐Aparicio, C., Blanco, F., Castro, M. E., Guijarro, M. V., Fominaya, J. M., Link, W., Martínez, J. F., Moneo, V., Renner, O., et al. (2003) · Revista de Oncología · doi:10.1007/bf02711481 · Cited by 6
Time-dependent regulation of apoptosis by aen and bax in response to 2-Aminoanthracene dietary consumption
Gato, W. E., Hales, D. B., McGee, S. R., & Means, J. C. (2014) · Toxicology International · doi:10.4103/0971-6580.128796 · Cited by 5
The Genetics of Melanoma
Gray‐Schopfer, V. C., & Bennett, D. C. (2006) · Wiley eBooks · doi:10.1002/9780470987100.ch24 · Cited by 6
Familial Melanoma Genes, Melanocyte Immortalization, and Melanoma Initiation
Bennett, D. C. (2007) · Humana Press eBooks · doi:10.1007/978-1-59259-994-3_10 · Cited by 5
Long noncoding RNA, PURPL is associated with aneuploidy and its magnitude of expression level is dependent on P53 status
Malakar, P. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1410308 · Cited by 5
Myositis ossificans mimicking bone surface osteosarcoma: case report with literature review
Werenski, J. O., Hung, Y. P., Chang, C. Y., Nielsen, G. P., & Lozano‐Calderón, S. A. (2024) · Apmis · doi:10.1111/apm.13422 · Cited by 4
Ribosomal Protein S4 X-Linked as a Novel Modulator of MDM2 Stability by Suppressing MDM2 Auto-Ubiquitination and SCF Complex-Mediated Ubiquitination
Ryu, S., Nakashima, H., Tanaka, Y., Mukai, R., Ishihara, Y., Tominaga, T., & Ohshima, T. (2024) · Biomolecules · doi:10.3390/biom14080885 · Cited by 4

Authors: Momand, J., Wu, H.-H., & Dasgupta, G.
Affiliations: California State University Los Angeles (US)
Corresponding author: Momand, Jamil
ORCID: Momand, Jamil
Wu, Hsiao-Huei
Venue: Gene
Publisher: Elsevier BV
Published: 2000-01
Volume: 242
Issue: 1-2
Pages: 15-29
ISSN: 0378-1119 (ISSN-L)
DOI: 10.1016/s0378-1119(99)00487-4
OpenAlex: W1973821009
Cited by: 641
References: 144
Citations by year: 2026: 6 · 2025: 11 · 2024: 17 · 2023: 19 · 2022: 24 · 2021: 10 · 2020: 17 · 2019: 16 · 2018: 22 · 2017: 14 · 2016: 17 · 2015: 31 · 2014: 21 · 2013: 21 · 2012: 24
FWCI: 4.03
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Gene (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
Keywords: MDM2, p53, tumor suppressor regulation, MDMX, conserved domains, p53 ubiquitination, proteasomal degradation, cell cycle arrest, apoptosis, oncogenes, cancer therapy
MeSH terms: Amino Acid Sequence, Animals, Gene Expression Regulation, Humans, Models, Biological, Molecular Sequence Data, Nuclear Proteins, Proto-Oncogene Proteins, Genes, Tumor Suppressor, Tumor Suppressor Protein p53, Sequence Homology, Amino Acid, Proto-Oncogene Proteins c-mdm2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

MDM2 — master regulator of the p53 tumor suppressor protein

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks